MYCN and neoplasm: As expected, administration of DZNep depleted MYCN (and Ezh2) concomitantly with a dramatic inhibition of primary tumor cell growth in vitro, whereas the enzymatic inhibitor GSK126 exhibited minimal effects (Fig. 6b).